Marc Robert Theoret
United States Food and Drug Administration · 312 works · 11,154 citations · h-index 54
Top works
- Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells
- IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T Cells
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
- High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens
- The Drug-Dosing Conundrum in Oncology — When Less Is More
- Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
- The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention
- U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program
- CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
- FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors
- Seamless Oncology-Drug Development
- Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction
- Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis
- Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice
- U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab
- Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy Trials
- The future of interleukin-2: enhancing therapeutic anticancer vaccines.
- Immunological and Antitumor Effects of IL-23 as a Cancer Vaccine Adjuvant
- Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival
- FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer